ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired ImmunityBio securities between January 19, 2026 and ...

Back in 2016, hundreds of jobs were expected for a drug manufacturing plant in the town of Dunkirk. The plant was built but ...

ImmunityBio's stock closed at $7.70 on Friday, marking a 6% gain that starkly contrasts with the company's current reality. The biotech firm is caught in a powerful tug-of-war between explosive ...

ImmunityBio has seen its price surge by 266 percent year-to-date—with shares already at $7.25 versus only $1.98 on December ...

Shiong’s earlier appearance on The Sean Spicer Show as suggesting uses beyond Anktiva’s approved indication. ・Soon-Shiong said the FDA classified the podcast discussion as direct-to-consumer ...

If you are an investor in ImmunityBio and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

Among the measures ImmunityBio has implemented are “expanded promotional review protocols,” executive training and external ...

The biotech company used misleading advertising to promote its flagship bladder cancer drug, the FDA concludes.

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

Kirby McInerney LLP reminds ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investors of the May 26, 2026 deadline to seek the role ...

The Portnoy Law Firm advises ImmunityBio, Inc., (“Super Micro” or the "Company") (NASDAQ: IBRX) investors of a class action on behalf of ...

View ImmunityBio Inc IBRX stock quote prices, financial information, real-time forecasts, and company news from CNN.